Year: 2013
Type: article
Study designs: Randomized Controlled Trial, Clinical Trial
Abstract: OBJECTIVE: To assess effectiveness of inpatient hybrid closed-loop control (HCLC) followed by outpatient sensor-augmented pump (SAP) therapy initiated within 7 days of diagnosis of type 1 diabetes on the preservation of β-cell function at 1 year. RESEARCH DESIGN AND METHODS: Sixty-eight individuals (mean age 13.3 ± 5.7 years; 35% female, 92% Caucasian) were randomized to HCLC followed by SAP therapy (intensive group; N = 48) or to the usual-care group treated with multiple daily injections or insulin pump therapy (N = 20). Primary outcome was C-peptide concentrations during mixed-meal tolerance tests at 12 months. RESULTS: Intensive-group participants initiated HCLC a median of 6 days after diagnosis for a median duration of 71.3 h, during which median participant mean glucose concentration was 140 mg/dL (interquartile range 134-153 mg/dL). During outpatient SAP, continuous glucose monitor (CGM) use decreased over time, and at 12 months, only 33% of intensive participants averaged sensor use ≥6 days/week. In the usual-care group, insulin pump and CGM use were initiated prior to 12 months by 15 and 5 participants, respectively. Mean HbA1c levels were similar in both groups throughout the study. At 12 months, the geometric mean (95% CI) of C-peptide area under the curve was 0.43 (0.34-0.52) pmol/mL in the intensive group and 0.52 (0.32-0.75) pmol/mL in the usual-care group (P = 0.49). Thirty-seven (79%) intensive and 16 (80%) usual-care participants had a peak C-peptide concentration ≥0.2 pmol/mL (P = 0.30). CONCLUSIONS: In new-onset type 1 diabetes, HCLC followed by SAP therapy did not provide benefit in preserving β-cell function compared with current standards of care.
Source: Diabetes Care
DOI: 10.2337/dc13-1074
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Funders: American Diabetes Association, Eli Lilly and Company, Pfizer, Sanofi, LifeScan, Yale University, Vanderbilt University, Diabetes Technology Management, Juvenile Diabetes Research Foundation United States of America, Vanderbilt University Medical Center, Dexcom, Georgia Clinical and Translational Science Alliance, Novo Nordisk, National Institutes of Health, School of Medicine, Indiana University, National Institute of Allergy and Infectious Diseases, National Institute of Diabetes and Digestive and Kidney Diseases, National Institute of Child Health and Human Development, National Center for Research Resources, NIH Clinical Center, National Center for Advancing Translational Sciences, Eunice Kennedy Shriver National Institute of Child Health and Human Development, University of Colorado School of Medicine, Anschutz Medical Campus
Awards: Stanford Center for Clinical and Translational Education and Research (SCCTER)UL1, Type 1 Diabetes TrialNet at Indiana University Clinical Center, Coordinating Center for Studies of Glucose Sensors in T*, Prevention of Nocturnal Hypoglycemia: Effect on Neurologic Outcome in Toddlers, G2263230212, G2365005589, G2473351280, G2683268942, Spectrum Stanford Center for clinical and Translational Research and Education, Stanford Center for Clinical and Translational Education and Research (SCCTER)UL1, G36923461, Indiana Clinical and Translational Science Institute (UL1), G5679716143, Cooperative Multicenter Diabetes Research Network for Hypoglycemia Prevention, TrialNet at Stanford University, Colorado Clinical and Translational Sciences Institute, Vanderbilt University: Clinical Center Application, Type 1 Diabetes TrialNet, Type 1 diabetes TrialNet Center at Yale University, The Vanderbilt Institute for Clinical and Translational Research (VICTR), Yale University Clinical and Translational Science Award Program, TrialNet: Diabetes Type 1 Prevention, G9000046657, Yale Diabetes Research Center, Yale Study of Closed-Loop Automated Glucose Control for Hypoglycemia Prevention, Colorado Clinical and Translational Science Institute (UL1)
OpenAlex ID: W2028990915
